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OBJECTIVE—Common variants in the gene TCF7L2 confer the
largest effect on the risk of type 2 diabetes. The present study
was undertaken to increase our understanding of the mecha-
nisms by which this gene affects type 2 diabetes risk.
RESEARCH DESIGN AND METHODS—Eight subjects with
risk-conferring TCF7L2 genotypes (TT or TC at rs7903146) and
10 matched subjects with wild-type genotype (CC) underwent 5-h
oral glucose tolerance test (OGTT), isoglycemic intravenous
glucose infusion, and graded glucose infusion (GGI). Mathemat-
ical modeling was used to quantify insulin-secretory proﬁles
during OGTT and glucose infusion protocols. The incretin effect
was assessed from ratios of the insulin secretory rates (ISR)
during oral and isoglycemic glucose infusions. Dose-response
curves relating insulin secretion to glucose concentrations were
derived from the GGI.
RESULTS—-cell responsivity to oral glucose was 50% lower
(47  4 vs. 95  15  10
9 min
1; P  0.01) in the group of
subjects with risk-conferring TCF7L2 genotypes compared with
control subjects. The incretin effect was also reduced by 30%
(32  4 vs. 46  4%; P  0.02) in the at-risk group. The lower
incretin effect occurred despite similar glucose-dependent insu-
linotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)
responses to oral glucose. The ISR response to intravenous
glucose over a physiologic glucose concentration range (5–9
mmol/l) was similar between groups.
CONCLUSIONS—The TCF7L2 variant rs7903146 appears to
affect risk of type 2 diabetes, at least in part, by modifying the
effect of incretins on insulin secretion. This is not due to reduced
secretion of GLP-1 and GIP but rather due to the effect of
TCF7L2 on the sensitivity of the -cell to incretins. Treatments
that increase incretin sensitivity may decrease the risk of type 2
diabetes. Diabetes 59:479–485, 2010
R
ecently, polymorphisms in the transcription fac-
tor 7-like 2 gene (TCF7L2) have been associated
with type 2 diabetes (1), increasing risk 1.46-
fold (2). Current evidence suggests that TCF7L2
increases the risk for type 2 diabetes by reducing glucose-
induced insulin secretion. In the Diabetes Prevention
Program, carriers of the T allele (rs79012146 or
rs12255372) had signiﬁcantly lower values for insulin/
glucose ratio and insulin response than CC homozygotes
(3). The mechanisms for reduced insulin secretion are
uncertain. TCF7L2 is a transcription factor involved in the
Wnt signaling pathway and is ubiquitously expressed (4).
Thus, one possibility is it has direct effects on the pancre-
atic -cell. Another possibility is that there is an effect on
proglucagon gene expression in intestinal endocrine cells,
thereby reducing the incretin response to oral nutrients
(5). In turn, this would be expected to lead to reduced
insulin secretion.
Indeed, several studies have reported reduced insulin
secretion after an oral glucose tolerance test (OGTT) in
subjects with TCF7L2 variants using ratios between insu-
lin and glucose levels such as insulinogenic index (3,6,7).
Reduced insulin secretion in response to oral compared
with intravenous glucose has also been reported (8,9),
consistent with alterations in the incretin system. Studies
that have used intravenous glucose to assess the direct
effects on the pancreatic -cell have yielded mixed results.
Some studies have shown diminished insulin responses to
standard intravenous glucose tolerance tests (10–13),
whereas others have shown no effect of TCF7L2 variants
on the response to hyperglycemic clamp or Arg (9,14,15).
The effect of TCF7L2 polymorphisms on insulin action is
also unclear. Several studies have shown no change in
insulin sensitivity (6,8), whereas other studies have shown
increased (3,14) or decreased (9,11) insulin sensitivity.
The present study was undertaken in an attempt to
clarify the effect of TCF7L2 on insulin secretion. Certain
features of the study design set this study apart from
previous studies. All subjects had normal or only mildly
impaired glucose tolerance, thus avoiding confounding ef-
fects of hyperglycemia on insulin secretion. Insulin secretory
responses to oral glucose derived by mathematical modeling
of peripheral C-peptide were compared at the same plasma
glucose concentrations achieved by intravenous infusion of
glucose. Insulin sensitivity was also quantiﬁed during the
OGTT. Finally, the effects of the at-risk variant in TCF7L2 on
the dose-response relationships between intravenous glu-
cose and insulin secretion were assessed across a physio-
logic range of glucose concentrations.
RESEARCH DESIGN AND METHODS
Eight subjects with the risk-conferring genotype (TT [seven subjects] or TC
[one subject] at rs7903146) and ten age-, sex-, and BMI-matched subjects with
the wild-type genotype (CC at rs7903146) participated. All subjects were
nondiabetic, younger than 65 years, in good general health and with stable
weight for 6 months, and were recruited using advertisements. They
were unrelated and had no family history of type 2 diabetes. The studies were
approved by the Human Research Protective Ofﬁce Committee at Washington
University School of Medicine and written informed consent was obtained from
each participant.
Study protocols. The subjects underwent three separate protocols designed
to test pancreatic -cell secretion and the incretin effect. Insulin secretion was
assessed during the 5-h OGTT and in response to graded glucose infusion
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diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 479(GGI). The incretin effect was assessed by comparing insulin secretion in
response to oral glucose with the response to an isoglycemic intravenous
glucose infusion designed to match the plasma glucose concentrations
achieved after oral glucose.
The subjects were instructed to adhere to their regular diet and to refrain
from exercise for 3 days before the studies. All studies were performed in the
Intensive Research Unit of the Washington University Institute for Clinical and
Translational Sciences after an overnight fast with the subjects in the
recumbent position. Intravenous cannulae were placed in a forearm vein for
blood withdrawal, and the forearm was warmed to arterialize the venous
sample. When necessary, a second catheter was placed for administration of
glucose or insulin as described below.
Five-hour oral OGTT. At time 0, participants ingested a 75-g glucose load.
Blood samples were collected at 10, 0, 10, 20, 30, 60, 90, 120, 150, 180, 240,
and 300 min after glucose ingestion to determine plasma glucose, insulin, and
C-peptide concentrations.
Isoglycemic intravenous glucose infusion. Intravenous infusions of glu-
cose (20% dextrose) were designed to reproduce the plasma glucose proﬁle
after oral glucose ingestion. Accuracy was assured by repeatedly measuring
plasma glucose concentrations, which allowed frequent adjustments of the
infusion rate according to deviations from the proﬁle that was to be mimicked.
Blood samples were drawn and treated as described for OGTT.
Graded glucose infusion. GGI involves the intravenous administration of
glucose at progressively increasing rates (1, 2, 3, 4, 6, and 8 mg/kg per min) for
40 min each, as we have previously described (16,17). This protocol raises the
plasma glucose concentration from basal to mildly hyperglycemic levels and
is used to deﬁne the dose-response relationships between glucose and insulin
secretion. To compare each subject’s plasma insulin response at the same
plasma glucose level, the best-ﬁt quadratic curve (using SigmaPlot Version 11;
SigmaPlot, San Jose, CA) was drawn through the data. The insulin concen-
tration at molar increments of plasma glucose beginning at 5 mmol/l was then
obtained by interpolation. The same technique applied to the insulin secretion
rate (ISR) provides a plot of the ISR at molar increments of plasma glucose
(18).
Body composition. Fat mass was measured using dual energy X-ray absorp-
tiometry (Delphi 4500-W; Hologic, Waltham, MA).
Analyses. The areas under the curve (AUCs) were calculated using the
trapezoid method (19).
Indexes of -cell function were estimated from plasma glucose and
C-peptide concentrations using the oral minimal model of C-peptide secretion
and kinetics (20,21) and incorporating parameters for C-peptide kinetics and
volume of distribution as measured by Van Cauter et al. (22). This model
calculates the ISR (pmol/min) as a function of time and several indexes of
-cell responsivity: 1) dynamic responsivity index (d [10
9]), which is an
index of insulin secretion in response to the rate of change in glucose
concentration; 2) static responsivity index (s [10
9 min
1]), which is an index
of insulin secretion in response to a given glucose concentration; and 3)
overall responsivity index (o [10
9 min
1]), which is a global sensitivity-to-
glucose index of postprandial insulin secretion.
The calculation of incretin effects from estimates of -cell secretory
responses is based on the assumption that after glucose ingestion, the
pancreas is stimulated by the increase in plasma glucose and the added effect
of incretin factors secreted by the intestine. Thus, intravenous glucose
infusion (IGI) provides a measure of the -cell secretory response to the
glucose stimulus in the absence of superimposed incretin effects. The incretin
effect is calculated from the insulin secretion response (SR) to oral and
intravenous glucose according to the following formula (23):
Incretin efect SRoral SRisoglycemiciv
SRoral
 100%
The dose-response relationship between ISR and glucose over the physio-
logical range was determined from the GGI. ISRs and glucose concentrations
used in the analysis represented the average of the values between 10 and 40
min at each glucose infusion rate. Mean ISR for each glucose infusion rate was
then plotted against the corresponding mean glucose concentration to deﬁne
the dose-response relationship. The slope of the line relating these two
variables provided a measure of the sensitivity of the -cell to glucose.
Whole-body insulin sensitivity was estimated using the oral glucose mini-
mal model (24,25), which has been shown previously to be well correlated
with the M value from the euglycemic hyperinsulinemic clamp (26).
Insulin clearance rate was calculated by dividing the ISR AUC by the
insulin AUC (16).
Biochemical measurements. Plasma glucose was measured immediately
using an automated glucose analyzer (Yellow Springs Instruments, Yellow
Springs, OH). Plasma insulin, C-peptide, and glucagon were measured by
double-antibody radioimmunoassays (Linco Research, St. Louis, MO). Human
glucose-dependent insulinotropic polypeptide (GIP; total) ELISA kit was used
for the quantiﬁcation of human GIP in plasma samples (Linco Research). This
kit has 100% cross-reactivity to human GIP (1–42) and GIP (3–42). Human
(total) electrochemiluminescent GLP-1 assay kit was used for the quantiﬁca-
tion of human glucagon-like peptide 1 (GLP-1; Meso Scale Discovery, Gaith-
ersburg, MD). This kit has 100% cross-reactivity to human GLP-1 (7–36) amide,
human GLP-1 (9–36) amide, GLP-1 (1–36) amide, GLP-1 (7–37), and GLP-1
(1–37).
Genotyping. DNA was prepared from peripheral blood lymphocytes and the
TCF7L2 polymorphisms (dbSNP rs7903146) typed using a TaqMan SNP
Genotyping Assay (Applied Biosystems, Foster City, CA).
Statistical analyses. Group differences in demographics and parameters of
glucose homeostasis were compared using the two-tailed unpaired Student t
tests for continuous variables and the Fisher exact test for categorical
TABLE 1
Anthropometrics and metabolic data of study participants
Control, CC
genotype
TCF7L2 genotypes
TT and TC P
n 10 8
Demographics
Age (years) 44.8  2.5 43.3  4.5 0.80
Women (%) 80 90 0.64
Caucasian/African American (n) 7/3 6/2 0.64
Body weight (kg) 92.3  4.1 93.8  5.4 0.80
BMI (kg/m
2) 31.9  1.3 34.2  2.1 0.32
Body fat (%) 38.9  2.1 38.2  3.1 0.85
Glucose homeostasis
Fasting glucose (mmol/l) 5.3  0.1 5.3  0.2 0.70
2-hour glucose (mmol/l) 7.7  0.3 8.6  0.5 0.09
Hemoglobin A1C (%) 5.7  0.5 5.7  0.5 0.92
Insulin secretion indices
Static -cell responsivity s (10
9 min
1) 67.4  8.8 40.7  3.7 0.02
Dynamic -cell responsivity d (10
9) 1,119  265 662  147 0.18
Overall -cell responsivity o (10
9 min
1) 94.4  15.4 46.6  4.2 0.01
Insulin sensitivity SI (10
3 min
1 per pmol/l) 14.2  2.4 15.3  2.5 0.41
Insulin clearance (ml/min) 1,941  163 2,157  38,122 0.49
Data are means  SE. Statistically signiﬁcant P values are shown in bold.
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compared using two-tailed unpaired Student t tests. SPSS Version 15.0 (SPSS,
Chicago, IL) was used for all statistical analyses. A P value  0.05 was
considered statistically signiﬁcant. Results are reported as mean  SE.
RESULTS
The group with the at-risk genotype (TT and TC) at
rs7903146 and the control group (CC genotype) were well
matched for age, sex, and body weight and composition
(Table 1). Both groups had normal fasting glucose concen-
trations and hemoglobin A1C. Two-h glucose and glucose
AUC tended to be greater in the at-risk group (Table 1, Fig.
1) but the differences did not reach statistical signiﬁcance.
The static -cell responsivity (s) and dynamic -cell
responsivity (d) to oral glucose tended to be lower in the
at-risk group than in the control group, with the difference
in the former reaching signiﬁcance (P  0.02). Consistent
with these ﬁndings, the overall -cell responsivity (o)
was signiﬁcantly lower (P  0.01), by 50% in the at-risk
group (Table 1). Insulin sensitivity and insulin clearance
rates were similar between the groups (P 	 0.05).
The plasma glucose proﬁle in the OGTT and IGI were
well matched in both groups (Table 2, Fig. 1). Consistent
with incretin effects in both groups, the AUCs for insulin
and C-peptide (Table 2, Fig. 1) and the AUCs for static,
dynamic, and overall ISRs (Table 2, Fig. 2) were lower in
the IGI than in the OGTT. However, subjects with the
at-risk TCF7L2 genotypes had signiﬁcantly reduced
incretin responses for insulin AUC (41 vs. 59%; P 
0.004), C-peptide AUC (32 vs. 45%; P  0.03), and overall
insulin secretory response to glucose AUC (32 vs. 46%;
P  0.02).
By contrast, both the GLP-1 (AUC: 3.2  0.6 vs. 2.9 
0.4  10
3 pg/ml  min; P  0.67) and GIP (AUC: 4.4  1.0
vs. 3.3  0.4  10
3; P  0.31) responses to oral glucose
were similar between the two groups (Fig. 3).
The GGI demonstrated that the ISR-glucose dose-re-
sponse relationships were not different (AUC: 1.7  0.2 vs.
2.0  0.3 10
3 pmol/min  mmol/l; P  0.41) between
groups (Fig. 4) over a physiologic range of glucose con-
centrations (5–9 mmol/l).
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FIG. 1. Plasma glucose, insulin, and C-peptide concentrations during the 5-h OGTT (F) and isoglycemic intravenous glucose infusion (‚)i n
control subjects and carriers of the at-risk TCF7L2 variant. Shaded areas indicate the incretin effects. P values indicate the signiﬁcance of the
differences in incretin effects between groups. Values are means  SE.
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subject with TC genotype was excluded from the analyses
(s, 43.3  3.4 vs. 67.5  8.8 10
9 min
1, P  0.04; o,
49.5  3.8 vs. 94.5  15.4, P  0.03), although they were
borderline signiﬁcant for difference in incretin effect
(34.3  4.3 vs. 45.5  4.1%; P  0.08).
DISCUSSION
The present study used the isoglycemic intravenous glu-
cose infusion (IGI), the deﬁnitive test of the incretin effect,
to examine the incretin effect in subjects with a TCF7L2
variant that enhances type 2 diabetes risk. Using measure-
ments of insulin secretion in response to oral and matched
intravenous infusions of glucose, the incretin effect was
reduced by 30% and this was consistent with the 50%
reduction in overall -cell responsivity to glucose demon-
strated during the OGTT. The reduced incretin effect was
accompanied by normal levels of GIP and GLP-1, suggest-
ing a reduced ability of the pancreatic -cell to respond to
incretins. Another new ﬁnding is that the defect in insulin
secretion appears to be selective for oral glucose and is
not present in response to intravenous glucose. Thus, the
graded glucose infusion study demonstrated that insulin
secretory response to intravenous glucose over a physio-
logic range of glucose concentrations is well preserved in
subjects with type 2 diabetes–associated genotypes. The
diminished -cell response to oral relative to intravenous
glucose is consistent with a key abnormality in the entero-
insular axis in subjects with diabetes-associated TCF7L2
genotype.
Although the incretin effect was reduced in subjects
with the diabetes-risk genotypes, the concentrations of
GLP-1 and GIP after oral glucose ingestion were not
different from those in control subjects. We measured total
rather than intact levels of GLP-1 and GIP. However, a
previous study showed that the pattern of GLP-1 and GIP
release appears similar when total or active levels are
measured (27). Our results are consistent with the results
of previous studies that have reported similar total GLP-1
and GIP levels independent of TCF7L2 genotype (8,9). Our
study assessed the entire secretory proﬁle of both GIP and
GLP-1 during the course of a 5-h OGTT, something not
consistently done in previous studies. Our results expand
and strengthen the evidence that the incretin secretory
capacity is normal in subjects with at-risk and non–at-risk
TCF7L2 genotypes, suggesting an inability of the pancre-
atic -cell in subjects with an at-risk genotype to appro-
priately respond to normal concentrations of GLP-1 and
GIP. This conclusion is consistent with data from two
previous studies. Scha ¨fer et al. (14) and Pilgaard et al.
(9) reported that the GLP-1– and/or GIP-induced insulin
secretion during a hyperglycemic clamp is reduced in
subjects with the at-risk TCF7L2 genotype. In the latter
study, the reduced insulin response occurred at GIP and
GLP-1 concentrations administered to closely mimic
physiologic concentrations (120 and 1,000 pmol/l,
respectively) and at glucose concentrations close to
physiologic postprandial levels of glucose (10 mmol/
l), conditions that approximate those in the IGI in the
present study. Collectively, these ﬁndings point to a
TABLE 2
AUCs for glucose, hormones, and the incretin effect
Study
Control, CC
genotype
TCF7L2 genotypes
TT and TC P
Glucose AUC (10
3 mmol/l  min)
OGTT 1.9  0.1 2.1  0.5 0.08
IGI 1.9  0.9 2.0  0.5
P 0.65 0.43 0.17
Insulin AUC (10
3 pmol/l  min)
OGTT 107.0  23.3 107.2  30.4 0.99
IGI 45.2  11.1 64.2  18.8 0.35
P 0.02 0.25
Incretin effect (%) 58.5  3.7 40.6  4.1 0.004
C-peptide AUC (10
3 pmol/l  min)
OGTT 703.7  63.9 729.4  61.8 0.77
IGI 392.0  54.3 498.5  56.4 0.17
P 0.001 0.02
Incretin effect (%) 45.1  4.1 32.2  3.4 0.03
Static ISR AUC (10
3 pmol  min)
OGTT 152.2  15.3 170.2  17.6 0.44
IGI 93.9  13.8 123.4  18.4 0.20
P 0.008 0.09
Incretin effect (%) 39.2  4.9 29.2  3.5 0.12
Dynamic ISR AUC (10
3 pmol  min)
OGTT 26.7  3.2 15.5  3.4 0.19
IGI 5.3  0.8 5.8  1.9 0.77
P 0.006 0.03
Incretin effect (%) 71.3  6.5 42.8  22.3 0.12
Overall ISR AUC (10
3 pmol  min)
OGTT 179.9  16.9 185.7  19.5 0.79
IGI 99.1  13.6 129.4  18.2 0.19
P 0.001 0.05
Incretin effect (%) 45.5  4.1 31.6  3.6 0.02
Data are means  SE. IGI, isoglycemic intravenous glucose infusion. Statistically signiﬁcant P values are shown in bold.
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creatic -cell in subjects with type 2 diabetes–associ-
ated TCF7L2 genotypes.
The molecular mechanisms responsible for the reduced
-cell response to GLP-1 and GIP as a function of TCF7L2
genotype have not been deﬁned and warrant further
investigation. TCF7L2 is a Wnt signaling-associated tran-
scription factor that plays an important role in the synthe-
sis of GLP-1 in intestinal L-cells (4). It was thus anticipated
that genetic variation in TCF7L2 would lead to reduced
secretion of GLP-1 and GIP. Clearly this is not the case. In
addition, the diabetes-associated variants in TCF7L2 have
been shown to have increased, rather than decreased, islet
levels of TCF7L2 mRNA (8). Interestingly, Shu et al. (28)
recently reported that increased levels of TCF7L2 mRNA
in -cells are actually associated with decreased TCF7L2
proteins, indicating altered regulation at a posttranscrip-
tional level. The reduction in TCF7L2 protein was found to
correlate with downregulation of GIP and GLP receptors,
thus resulting in decreased Akt phosphorylation and Akt-
mediated Foxo-1 phosphorylation, and, therefore, im-
paired -cell function.
Based on the results of a graded intravenous infusion of
glucose, our study is the ﬁrst to demonstrate that the
dose-response relationships between glucose and insulin
secretion over the physiologic range of glucose concentra-
tions (5–9 mmol/l) are relatively well preserved in subjects
with at-risk and non–at-risk TCF7L2 genotypes. These
ﬁndings may not be surprising, given that the response to
intravenous glucose is not inﬂuenced by intestinal incretin
peptides. Previous studies that have examined the direct
effect of intravenous glucose on the pancreatic -cell using
various protocols have yielded inconsistent results. For
example, intravenous glucose tolerance tests showed that
the acute insulin response (AIR) was unchanged (9,14,15)
or reduced (12,13) as a function of TCF7L2 genotype.
Moreover, hyperglycemic clamp with Arg showed that the
AIR was unchanged (at 10 mmol/l glucose) (14), whereas
the same test showed that AIR was reduced (at 14 and 24
mmol/l glucose) in another study (8). Although the latter
might suggest that the maximal insulin secretory response
is impaired in subjects with a diabetes-associated TCF7L2
genotype, the physiologic signiﬁcance of this ﬁnding has
yet to be determined. On the other hand, the results from
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FIG. 2. Insulin secretory indexes during the 5-h OGTT (F) and isoglycemic intravenous glucose infusion (‚) in control subjects and carriers of
the at-risk TCF7L2 variant. Shaded areas indicate the incretin effects. P values indicate the signiﬁcance of the differences in incretin effects
between groups. Values are means  SE.
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of glucose concentrations (5–9 mmol/l), TCF7L2 genotype
does not signiﬁcantly affect the insulin response to intra-
venous glucose, as evidenced by the normal -cell dose
response.
Finally, we also demonstrated that the TCF7L2 geno-
type does not signiﬁcantly affect overall insulin sensitivity.
We used the oral glucose minimal model to derive insulin
sensitivity index, which has the advantage of being simul-
taneously assessed with -cell responsivity during the
OGTT. The sensitivity index measures the overall effect of
insulin to stimulate glucose disposal and inhibit glucose
production, and has been validated against the euglyce-
mic-hyperinsulinemic clamp (26). Indeed, our results are
consistent with previous studies using euglycemic-hyper-
insulinemic clamp that have also reported normal whole-
body insulin sensitivity in subjects with diabetes-
associated genotypes (8,14). However, interestingly, two
recent studies (9,11) have reported decreased hepatic
insulin sensitivity in subjects with diabetes-associated
genotypes, possibly attributed to the lower insulin levels
and/or a direct or indirect effect of TCF7L2 on endogenous
glucose production. The latter ﬁndings await conﬁrmation
in other studies (29).
In summary, the present study provides evidence that
TCF7L2 affects the insulin secretory response to oral
glucose with an impaired incretin effect (30% reduction)
due to impaired GIP- and GLP-1–induced insulin secretion
rather than incretin deﬁciency in subjects with the at-risk
TCF7L2 rs7903146 genotype. In contrast, the -cell dose
response to intravenous glucose over a physiologic range
of glucose concentrations is normal. We also found no
evidence of impairment in whole-body insulin sensitivity.
Further studies are needed to elucidate the mechanisms
for the lack of response to incretins as a function of
TCF2L7 genotype. Our ﬁndings raise the possibility that
increasing incretin levels through pharmacotherapy might
overcome incretin resistance and thus decrease the risk of
type 2 diabetes due to genetic variation in TCF7L2.
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FIG. 4. Insulin secretory rates plotted against glucose infusion rate (A)
and plasma glucose (B) during the graded-glucose infusion in control
subjects (‚) and carriers of the at-risk TCF7L2 variant (F). There
were no signiﬁcant between group differences in AUCs (P < 0.05).
Values are means  SE.
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